E3 PreliminaryPreliminaryPEM unclearReview-NarrativePeer-reviewedReviewed
The glutathione system: a new drug target in neuroimmune disorders.
Morris, Gerwyn, Anderson, George, Dean, Olivia et al. · Molecular neurobiology · 2014 · DOI
Quick Summary
This review examines glutathione (GSH), a naturally occurring substance in our cells that protects against damage and helps our immune system work properly. When glutathione levels drop, cells become more stressed and inflamed, which may contribute to ME/CFS and other conditions affecting the brain and immune system. The authors suggest several potential treatments—including supplements like N-acetyl cysteine and natural compounds like curcumin—that might help restore glutathione levels.
Why It Matters
For ME/CFS patients, this work provides a unifying biochemical mechanism that could explain multiple disease features: energy dysfunction, immune dysregulation, and neurological symptoms. If GSH depletion is indeed central to ME/CFS pathology, it opens the door to testable therapeutic approaches and identifies specific biological targets for drug development.
Observed Findings
- Glutathione depletion correlates with increased oxidative and nitrosative stress (ROS/RNS) and inflammatory mediators in various disease states
- GSH acts as an essential cofactor for antioxidant enzymes (glutathione peroxidases, GSH S-transferases) that detoxify harmful molecules
- GSH dysfunction disrupts key intracellular signaling pathways including NF-κB, p53, and Janus kinases
- GSH depletion impairs mitochondrial complex I function and can trigger apoptosis
- GSH depletion compromises T cell activation and immune system homeostasis
Inferred Conclusions
- GSH depletion is a mechanistic link between oxidative stress, mitochondrial dysfunction, and immune dysregulation in neuroimmune diseases including ME/CFS
- Therapeutic strategies to restore GSH—including N-acetyl cysteine, Nrf-2 activation, and phytochemicals—warrant clinical investigation in ME/CFS
- GSH restoration may address multiple disease pathways simultaneously, affecting energy metabolism, inflammation, and neurological function
Remaining Questions
- Are glutathione levels actually depleted in ME/CFS patients compared to healthy controls, and does depletion severity correlate with symptom severity?
- Which GSH-restoring intervention (NAC, curcumin, dimethyl fumarate, etc.) is most effective and bioavailable in ME/CFS, and at what doses?
What This Study Does Not Prove
This review does not prove that GSH depletion causes ME/CFS or that GSH-restoring therapies will effectively treat the disease. It presents correlational evidence and mechanistic reasoning rather than clinical trial data. Direct measurement of GSH levels in ME/CFS patients and controlled trials of proposed interventions remain necessary.
Tags
Symptom:Cognitive DysfunctionFatigue
Biomarker:MetabolomicsBlood Biomarker
Method Flag:Exploratory Only
Metadata
- DOI
- 10.1007/s12035-014-8705-x
- PMID
- 24752591
- Review status
- Editor reviewed
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 12 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.